eNeura, Inc. Announces Series D Financing

BALTIMORE, Feb. 6, 2018 /PRNewswire/ -- eNeura, Inc., a privately held medical technology company developing non-invasive, non-drug treatment and prevention of migraine headache, announced today that it had completed a Series D financing led by Camden Partners Nexus, an investment group based in Baltimore, Maryland.  The proceeds of the Series D financing will be used for the commercial expansion of the Company's sTMS mini neuromodulation device for the acute treatment and prevention of migraine. 

"In the past, migraine patients in the U.S. have had to depend on combinations of pharmaceutical products, each with potentially unpleasant side-effects, to both treat and prevent migraine," said David K. Rosen, President and CEO of eNeura. "With this round of investment led by Camden Partners, we will be able to offer patients access to a safe, effective and cost-effective treatment and preventative for migraine headache."

Following the U.S. Food and Drug Administration (FDA) clearance of sTMS for acute treatment and prevention of migraine headache in mid 2017, eNeura has launched its newest generation of sTMS (single-pulse Transcranial Magnetic Stimulation) working with headache specialists and neurologists at headache centers across the U.S. 

"eNeura is establishing the market for non-invasive treatment and prevention of migraine headache through sTMS therapy," said Jacob Vogelstein, Managing Partner at Camden Partners Nexus. "Neuromodulation is the next great advancement in migraine treatment and prevention and we are pleased to have the opportunity to support eNeura's commercial efforts to expand sTMS access for patients."  

About eNeura

eNeura, Inc. is a privately held medical technology company that is pioneering the use of portable, non-invasive Transcranial Magnetic Stimulation devices for treatment of migraine. SpringTMS is a prescription-only device that utilizes single-pulse Transcranial Magnetic Stimulation (sTMS) to induce very mild electrical currents that can depolarize neurons in the brain. This process is thought to interrupt the abnormal hyperactivity associated with migraine. Prescribed by physicians but designed for patient use, it is the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office or on the go. SpringTMS is now approved in the U.S. and Europe for both the acute treatment of migraine and migraine prevention. For more information about eNeura, please visit http://www.eneura.com.

Media Contact:
Jason Rando
Tiberend Strategic Advisors, Inc.
212-375-2665
[email protected]

SOURCE eNeura, Inc.

Related Links

http://www.eneura.com